Literature Review: saRNA-Mediated HIF-1 Alpha Upregulation Enhances CAR-T Cell Function in Hypoxic Microenvironments and Cytokine Quantification with ELISA Kits

Home

Product Application

October 30, 2026

Clicks：124

Literature Review: saRNA-Mediated HIF-1α Upregulation Enhances CAR-T Cell Function in Hypoxic Microenvironments — Cytokine Quantification with Absin ELISA Kits

1. Publication Overview

• Title: Overexpression of HIF-1α via small activating RNA enhances CAR-T cell function in hypoxic microenvironments

• Journal: Pharmacological Research (2026, Vol. 229; latest IF = 12.2; CAS Q1 Top; SCI-indexed, open access)

• DOI: 10.1016/j.phrs.2026.108235

2. Core Conclusions

The study established a piggyBac non-viral transposon platform for CAR-T manufacturing and screened saRNAs for optimal specific activation of the endogenous HIF1A gene. HIF1A-overexpressing CAR-T cells (HIF1A^OE-CAR-T) underwent dual metabolic reprogramming — GLUT1-driven glycolytic upregulation plus Nrf2/PGC-1α-mediated mitochondrial protection — resulting in enhanced cytotoxicity, cytokine secretion and tumor spheroid infiltration under 1% hypoxia, together with reduced T cell exhaustion. The strategy was validated across both HER2 and NKG2D CAR models. In vivo, combination with an anti-CTLA4 nanobody produced synergistic solid tumor regression without evident organ toxicity, offering a safe non-viral approach to CAR-T therapy in hypoxic tumor microenvironments.

3. Role of Absin Products

The study used Absin human IL-2 (abs510001), human TNF-α (abs510006) and human IFN-γ (abs510007) ELISA kits to quantify key effector cytokines in CAR-T supernatants. These three sandwich ELISA kits accurately measured cytokine concentrations across normoxic and hypoxic treatment groups, directly demonstrating that HIF1A overexpression reverses hypoxia-mediated suppression of cytokine secretion. Their reproducibility and sensitivity met the quantitative demands of multiple in vitro assays, 3D tumor spheroid cultures and in vivo serum samples, providing essential quantitative support for CAR-T functional phenotyping.

4. Research Background

CAR-T therapy has achieved breakthrough efficacy in hematologic malignancies but performs poorly against solid tumors. The hypoxic, immunosuppressive tumor microenvironment (TME) is a central bottleneck: disorganized tumor vasculature and rapid proliferation create local oxygen tensions near 1%, which directly suppress CAR-T infiltration, promote T cell exhaustion and weaken cytotoxic factor release. Hypoxia-inducible factor HIF-1α is the master transcription factor of the hypoxic adaptive response, governing T cell glucose metabolism, mitochondrial homeostasis and chemokine receptor expression. However, sustained HIF-1α overexpression readily drives terminal T cell exhaustion, so achieving physiological, precisely controlled upregulation has been a major challenge.

Conventional viral CAR-T vectors carry risks of insertional mutagenesis, limited payload capacity and high cost. Small activating RNA (saRNA) targets gene promoters to activate endogenous transcription without introducing exogenous transgenes, offering a superior safety profile — but had not previously been combined with non-viral CAR-T systems for solid tumor immunotherapy. Prior work examined HIF-1α or saRNA individually; no study had integrated saRNA, piggyBac non-viral delivery and CAR-T metabolic reprogramming to address hypoxia tolerance in solid tumors. This work fills that gap.

5. Overall Research Logic

The study follows a seven-layer progression: clinical bioinformatics validation → saRNA tool development → in vitro 2D function → 3D tumor spheroid validation → metabolic mechanism → multi-CAR generality testing → in vivo combination therapy.

6. Module-by-Module Findings

Module 1 — Clinical bioinformatics and saRNA development. TCGA breast cancer cohort analysis confirmed that HIF1A overexpression correlates with advanced stage, poor prognosis and glycolytic reprogramming. Five saRNAs targeting the HIF1A promoter were designed; qPCR and Western blot screening identified saRNA-4 as the most potent activator, upregulating HIF1A mRNA and protein in both Jurkat and primary T cells.

Module 2 — piggyBac non-viral saRNA-HER2-CAR-T construction. A HER2 nanobody CAR construct carrying the saRNA cassette was built and electroporation conditions optimized. By day 9 post-electroporation, CAR transfection efficiency reached 84% ± 12.9%, with CD4/CD8 ratios and central memory T (Tcm) fractions comparable to untransduced T cells, and significantly higher HIF1A expression in the saRNA group.

Module 3 — In vitro cytotoxicity and cytokine function under normoxia/hypoxia. LDH cytotoxicity assays, cytokine ELISA and flow cytometry for CD4/CD8 and memory subsets (CD45RA/CCR7) were performed. Absin abs510001 (IL-2), abs510006 (TNF-α) and abs510007 (IFN-γ) kits were used to quantify cytokine levels in 24 h co-culture supernatants. Hypoxia significantly suppressed killing and the secretion of IL-2, IFN-γ, TNF-α, perforin and granzyme B in conventional CAR-T cells; HIF1A^OE-CAR-T cells fully reversed this suppression, with increased CD8 proportion, higher Tcm fraction and reduced exhaustion markers.

Module 4 — Generality testing with an NKG2D-CAR model. Replacing the CAR with the broadly applicable NKG2D specificity reproduced all in vitro phenotypes using the same Absin ELISA kits (IFN-γ, TNF-α). NKG2D-HIF1A^OE-CAR-T cells likewise showed hypoxia resistance, high cytotoxicity, elevated cytokine output and enrichment of CD8⁺ and memory T cells, confirming that the strategy is not antigen-specific.

Module 5 — 3D tumor spheroid infiltration and tumor suppression. Using mCherry-labeled SKBR3/DLD-1 spheroids, confocal imaging showed that HIF1A^OE-CAR-T cells penetrated the spheroid core, with markedly reduced mCherry fluorescence, substantially higher cytokine secretion measured by Absin ELISA kits, and downregulated exhaustion markers (PD-1, TIM-3, LAG-3).

Module 6 — Dual metabolic mechanism. Seahorse glycolytic stress testing (ECAR) and mitochondrial stress testing (OCR), metabolomics, ROS flow cytometry and Western blotting (GLUT1, Nrf2, PGC-1α, HIF-1α) showed that HIF1A^OE-CAR-T cells displayed significantly enhanced glycolytic capacity and maximal mitochondrial respiration under hypoxia. GLUT1 upregulation promoted glucose metabolism, while Nrf2/PGC-1α pathway activation reduced ROS and preserved mitochondrial integrity.

Module 7 — In vivo efficacy in a breast cancer xenograft with CTLA4 nanobody combination. In NOD-SCID mice bearing SKBR3-Luc tumors, HIF1A^OE-CAR-T monotherapy outperformed conventional CAR-T, and combination with an intraperitoneal CTLA4 nanobody (3 mg/kg) produced the strongest tumor regression and longest survival. Tumors showed increased CD3⁺ T cell infiltration and reduced Ki67, with no histopathological damage in heart, liver, kidney, spleen or lung. Absin ELISA kits were used to quantify serum IL-2, IFN-γ and TNF-α, confirming sustained in vivo CAR-T activation.

7. Summary: Scientific Value of the Absin ELISA Kits

• Gold standard for hypoxic functional quantification. The three double-antibody sandwich kits offer high sensitivity and low inter-assay variation, resolving subtle cytokine differences between normoxic and hypoxic conditions and between CAR-T groups, and providing reproducible quantitative evidence that HIF1A reverses hypoxia-induced immunosuppression.

• Standardized reagents across multiple models. Applicable to cell culture supernatant, tumor spheroid co-culture systems and mouse serum in humanized CAR-T studies, unifying detection standards and ensuring data continuity from in vitro assays to in vivo efficacy, consistent with the data quality requirements of high-impact journals such as Pharmacological Research.

• Supporting translational validation. In vivo serum cytokine quantification directly demonstrates persistent activation of HIF1A^OE-CAR-T in solid tumors, with further elevated effector molecules following CTLA4 combination, substantiating the clinical translation potential of this approach.

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc.

worldwide@absin.cn